This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.
We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.
Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.
We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.
Terms of use
Privacy Notice
System cookies (required)
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
Google Analytics
This is a web analytics service.
Processing company
Google Ireland Limited
Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
Marketing
Advertisement
Web Analytics
Technologies Used
Cookies
Pixel Tags
Data Attributes
IP address (anonymised)
Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
IP address
Date and time of visit
Usage data
Click path
App updates
Browser information
Device information
JavaScript support
Pages visited
Referrer URL
Downloads
Flash version
Location information
Purchase activity
Widget interactions
Legal Basis
In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
Art. 6 (1) (a) GDPR
Location of Processing
Republic of Serbia
Retention Period
The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
Alphabet Inc.
Facebook Pixel
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
Facebook Ireland Limited
4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
advertising
Marketing
Retargeting
Analyse
Tracking
Technologies Used
Cookies
Data Attributes
Pixel specific data
Http-Header
Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
Facebook user ID
Browser information
Usage data
Geräteinformationen
Non-sensitive custom data
Referrer URL
Pixel ID
Location information
Pixel specific data
User behaviour
Ads viewed
Interactions with advertisement, services, and products
Marketing information
Content viewed
IP address
Legal Basis
In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
Republic of Serbia
Retention Period
The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
Facebook Inc.
ENG
SRB
DEU
Home
About us
Business
Products
Responsibility
Career
Media
Blog
Contact
ENG
SRB
DEU
Home
About us
▾
Company profile
Mission and vision
Management
Representative offices
Production
Our history
Business
▾
R&D
Quality
Stakeholders
Code of Conduct
General conditions of business operations
Products
▾
Report adverse drug reactions
Responsibility
▾
Compliance
Social responsibility
Sustainable development
Career
▾
Corporate culture
Employees
Education of employees
Your career
Media
Blog
Contact
Home
›
Media
›
News
›
Hemofarm Celebrates 20 Years of Work of the Banja Luka Pharmaceutical Factory
Hemofarm Celebrates 20 Years of Work of the Banja Luka Pharmaceutical Factory
23. February 2023.
Hemofarm company, pharmaceutical leader in BiH and this region, marked the 20th anniversary of founding the pharmaceutical solid dosage forms factory in Banjaluka.
Modern facilities of Hemofarm Banjaluka are in compliance with the top international pharmaceutical standards accompanied with highly professional personnel. A record year in production of solid dosage forms is behind Hemofarm, and the output of these facilities in 2022 reached 1,707 billion tablets.
“Hemofarm has been breaking its own records and another record year has just passed. We are part of the unique STADA group, which strongly steps forward into the field of innovation in all segments of pharmaceutical development, and precisely the investments, as well as the expansion of the portfolio with modern therapies, demonstrate its determination to invest in this region. In the last five years alone, more than 20 million euros have been invested in the plants of the Banja Luka factory, and that number shows the Group's clear commitment to invest in Hemofarm”, said Ronald Seeliger, CEO of Hemofarm.
Saša Urošević, director of Hemofarm in B&H, pointed out that Hemofarm had invested for decades, both in the employee development through ongoing education and professional training, and in the production and portfolio development.
“Our portfolio in B&H comprises more than 370 products in different forms and dosages. Year after year, we have been improving it by adding contemporary generations of products to the satisfaction of our customers who are offered an ever increasing selection of good quality and affordable medicines. The consumers are also our starting point when it comes to production. We have been increasing its volume and maintaining the highest level of product quality confirmed by our compliance with the demanding European and global regulations, as well as the best practice in our industry. These are the very reasons why the well-known brands Grippostad and Coldrex will be packed in the plants in Banjaluka. Through all segments of our work, we are devoted to caring for people's health as a trusted partner”, stated Urošević.
The pharmaceutical factory in Banjaluka was opened in 2003, while in August 2006 Hemofarm became a part of the German STADA Group, one of the largest global generic companies. This company produces a significant number of products intended for sales in the EU countries, which is a confirmation of its modern concept, state-of-the-art technological equipment and competence of its employees.
Taken over from:
www.hemofarm.ba